<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509470</url>
  </required_header>
  <id_info>
    <org_study_id>P2007008</org_study_id>
    <nct_id>NCT00509470</nct_id>
  </id_info>
  <brief_title>Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine</brief_title>
  <acronym>ONEAST</acronym>
  <official_title>ONgoing Evaluation of Depressor Effect And Safety of Combination Therapy With Telmisartan and Low-dose Hydrochlorothiazide in Patients With Hypertension Uncontrolled on Amlodipine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokyo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare depressor effect and safety between combination
      therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In hypertensive patients whose blood pressure (BP) does not reach less than 140/90 mmHg with
      5mg/day of amlodipine are divided the following two groups and BP response, laboratory data,
      and adverse effects are compared. Group 1: 12 week combination therapy with telmisartan plus
      low-dose hydrochlorothiazide. Group 2: Amlodipine is continuously administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in office blood pressure</measure>
    <time_frame>After 12 week treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Home blood pressure in early morning and before going to bed 2) Changes in uric acid, total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, fasting plasma glucose (only in diabetic patients), hemoglobin A1c (only in diabetic patients</measure>
    <time_frame>After 12 week treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>telmisartan plus low-dose hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine is continuously administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan plus hydrochlorothiazide</intervention_name>
    <description>Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day</description>
    <arm_group_label>telmisartan plus low-dose hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  5 mg/day of amlodipine is administered for more than 3 months

          -  Systolic or diastolic blood pressure &gt;= 140/90 mmHg (more than 2 times measurements at
             outpatient clinic before start of the study)

          -  Outpatients

        Exclusion Criteria:

          -  Secondary hypertension including renovascular hypertension with single kidney or
             bilateral stenosis

          -  Administration of antihypertensives other than amlodipine

          -  Cardiovascular disease (cerebral hemorrhage, cerebral infarction, TIA, angina,
             myocardial infarction, acute renal failure) occurs less than 6 months before start of
             the study

          -  Serum creatinine &gt;= 2.0 mg/dl

          -  Severe hypertension (systolic or diastolic blood pressure &gt;= 180/110 mmHg) or
             malignant hypertension (hypertensive organ damage is rapidly developing)

          -  Chronic heart failure (NYHA class&gt;=III to VI)

          -  Contraindication of telmisartan or hydrochlorothiazide

          -  Hyper- (&gt;= 5.5 mEq/L) or hypo- (&lt;=3.5 mEq/l) potassemia

          -  Untreated hyperuricemia or uncontrolled hyperuricemia (serum uric acid &gt;= 8.0 mg/dl)

          -  Diabetic patients who require insulin therapy, uncontrolled diabetic patients
             (hemoglobin A1c &gt;=9.0%), or patients who possess the risk of hypoglycemic attack

          -  Patients inadequate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiro Fujita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2007</study_first_submitted>
  <study_first_submitted_qc>July 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokyo University</investigator_affiliation>
    <investigator_full_name>Hiroshi Satonaka</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

